These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27128325)

  • 1. A Scalable Synthesis of the Difluoromethyl-allo-threonyl Hydroxamate-Based LpxC Inhibitor LPC-058.
    Liang X; Gopalaswamy R; Navas F; Toone EJ; Zhou P
    J Org Chem; 2016 May; 81(10):4393-8. PubMed ID: 27128325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors.
    Titecat M; Liang X; Lee CJ; Charlet A; Hocquet D; Lambert T; Pagès JM; Courcol R; Sebbane F; Toone EJ; Zhou P; Lemaitre N
    J Antimicrob Chemother; 2016 Oct; 71(10):2874-82. PubMed ID: 27330072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of potent Gram-negative specific LpxC inhibitors.
    Mansoor UF; Vitharana D; Reddy PA; Daubaras DL; McNicholas P; Orth P; Black T; Siddiqui MA
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1155-61. PubMed ID: 21273067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Process in the Inhibitors of UDP-3-O-(R-3-hydroxyacyl)-Nacetylglucosamine Deacetylase (LpxC) Against Gram-Negative Bacteria.
    Liu F; Ma S
    Mini Rev Med Chem; 2018; 18(4):310-323. PubMed ID: 27739357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibacterial agents that target lipid A biosynthesis in gram-negative bacteria. Inhibition of diverse UDP-3-O-(r-3-hydroxymyristoyl)-n-acetylglucosamine deacetylases by substrate analogs containing zinc binding motifs.
    Jackman JE; Fierke CA; Tumey LN; Pirrung M; Uchiyama T; Tahir SH; Hindsgaul O; Raetz CR
    J Biol Chem; 2000 Apr; 275(15):11002-9. PubMed ID: 10753902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based discovery of LpxC inhibitors.
    Zhang J; Chan A; Lippa B; Cross JB; Liu C; Yin N; Romero JA; Lawrence J; Heney R; Herradura P; Goss J; Clark C; Abel C; Zhang Y; Poutsiaka KM; Epie F; Conrad M; Mahamoon A; Nguyen K; Chavan A; Clark E; Li TC; Cheng RK; Wood M; Andersen OA; Brooks M; Kwong J; Barker J; Parr IB; Gu Y; Ryan MD; Coleman S; Metcalf CA
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1670-1680. PubMed ID: 28302397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli.
    Barb AW; McClerren AL; Snehelatha K; Reynolds CM; Zhou P; Raetz CR
    Biochemistry; 2007 Mar; 46(12):3793-802. PubMed ID: 17335290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new class of UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) inhibitors for the treatment of Gram-negative infections: PCT application WO 2008027466.
    Cuny GD
    Expert Opin Ther Pat; 2009 Jun; 19(6):893-9. PubMed ID: 19473108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of the metal-dependent deacetylase LpxC from Yersinia enterocolitica complexed with the potent inhibitor CHIR-090 .
    Cole KE; Gattis SG; Angell HD; Fierke CA; Christianson DW
    Biochemistry; 2011 Jan; 50(2):258-65. PubMed ID: 21171638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The inhibitory and binding studies of methyl-sulfone hydroxamate based inhibitors against LpxC from drug resistant Moraxella catarrhalis using biophysical, biochemical and in silico approaches.
    Sharma A; Kumar V; Pratap S; Kumar P
    Int J Biol Macromol; 2018 Oct; 118(Pt B):1747-1762. PubMed ID: 30017978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors: a new class of antibacterial agents.
    Zhang J; Zhang L; Li X; Xu W
    Curr Med Chem; 2012; 19(13):2038-50. PubMed ID: 22414079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections.
    Montgomery JI; Brown MF; Reilly U; Price LM; Abramite JA; Arcari J; Barham R; Che Y; Chen JM; Chung SW; Collantes EM; Desbonnet C; Doroski M; Doty J; Engtrakul JJ; Harris TM; Huband M; Knafels JD; Leach KL; Liu S; Marfat A; McAllister L; McElroy E; Menard CA; Mitton-Fry M; Mullins L; Noe MC; O'Donnell J; Oliver R; Penzien J; Plummer M; Shanmugasundaram V; Thoma C; Tomaras AP; Uccello DP; Vaz A; Wishka DG
    J Med Chem; 2012 Feb; 55(4):1662-70. PubMed ID: 22257165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, structure, and antibiotic activity of aryl-substituted LpxC inhibitors.
    Liang X; Lee CJ; Zhao J; Toone EJ; Zhou P
    J Med Chem; 2013 Sep; 56(17):6954-6966. PubMed ID: 23914798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the UDP pocket of LpxC through amino acid analogs.
    Hale MR; Hill P; Lahiri S; Miller MD; Ross P; Alm R; Gao N; Kutschke A; Johnstone M; Prince B; Thresher J; Yang W
    Bioorg Med Chem Lett; 2013 Apr; 23(8):2362-7. PubMed ID: 23499237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular recognition by Escherichia coli UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase is modulated by bound metal ions.
    Hernick M; Fierke CA
    Biochemistry; 2006 Dec; 45(49):14573-81. PubMed ID: 17144651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecule LpxC inhibitors against gram-negative bacteria: Advances and future perspectives.
    Niu Z; Lei P; Wang Y; Wang J; Yang J; Zhang J
    Eur J Med Chem; 2023 May; 253():115326. PubMed ID: 37023679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, biological evaluation and molecular docking studies of benzyloxyacetohydroxamic acids as LpxC inhibitors.
    Szermerski M; Melesina J; Wichapong K; Löppenberg M; Jose J; Sippl W; Holl R
    Bioorg Med Chem; 2014 Feb; 22(3):1016-28. PubMed ID: 24412340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure of the LpxC deacetylase with a bound substrate-analog inhibitor.
    Coggins BE; Li X; McClerren AL; Hindsgaul O; Raetz CR; Zhou P
    Nat Struct Biol; 2003 Aug; 10(8):645-51. PubMed ID: 12833153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa.
    Mdluli KE; Witte PR; Kline T; Barb AW; Erwin AL; Mansfield BE; McClerren AL; Pirrung MC; Tumey LN; Warrener P; Raetz CR; Stover CK
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2178-84. PubMed ID: 16723580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Novel Inhibitors of LpxC Displaying Potent in Vitro Activity against Gram-Negative Bacteria.
    Surivet JP; Panchaud P; Specklin JL; Diethelm S; Blumstein AC; Gauvin JC; Jacob L; Masse F; Mathieu G; Mirre A; Schmitt C; Lange R; Tidten-Luksch N; Gnerre C; Seeland S; Herrmann C; Seiler P; Enderlin-Paput M; Mac Sweeney A; Wicki M; Hubschwerlen C; Ritz D; Rueedi G
    J Med Chem; 2020 Jan; 63(1):66-87. PubMed ID: 31804826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.